Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
VGIT vs XBI: how they differ
VGIT and XBI hold 0% of their weight in the same names, and XBI returned more over the year.
Vanguard Intermediate-Term Treasury Index Fund and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, VGIT and XBI hold 0% of their money in the same securities at the same weight.
| Only in VGIT | Only in XBI |
|---|---|
| United States Treasury Note/Bond 1.97% | Apogee Therapeutics Inc 1.49% |
| United States Treasury Note/Bond 1.94% | Moderna Inc 1.41% |
| United States Treasury Note/Bond 1.92% | Twist Bioscience Corp 1.41% |
| United States Treasury Note/Bond 1.92% | Oruka Therapeutics Inc 1.38% |
| United States Treasury Note/Bond 1.92% | Kymera Therapeutics Inc 1.36% |
| United States Treasury Note/Bond 1.89% | Viking Therapeutics Inc 1.31% |
| United States Treasury Note/Bond 1.89% | Praxis Precision Medicines Inc 1.29% |
| United States Treasury Note/Bond 1.87% | Erasca Inc 1.27% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and May 31, 2026.
| VGIT Vanguard Intermediate-Term Treasury Index Fund | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Vanguard | State Street |
| What it is | Intermediate-Term Treasury | SPDR S&P Biotech |
| Total return, 1 year | −1.2% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −18.7 pts | +46.5 pts |
| Expense ratio | 0.03% | 0.35% |
| Holdings | 103 | 150 |
VGIT in plain words
VGIT is a bond fund tracking the Intermediate-Term Treasury. Over the year to Sep 11, 2026 it returned −1.2% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.03% a year. It sat 3.7% below its high of Aug 4, 2020 on Sep 11, 2026.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, VGIT or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, VGIT returned −1.2% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, VGIT or XBI?
- VGIT charges 0.03% a year and XBI charges 0.35%, so VGIT is cheaper. Fees come from each fund's prospectus.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, VGIT against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/VGIT-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources